BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial

Reuters

Yesterday

BUZZ-Edgewise <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on positive safety data from heart disease drug trial

** Shares of biotech company Edgewise Therapeutics EWTX.O rise 20.4% to $26.18

** Company says its experimental heart disease drug showed positive safety results in a mid-stage study

** EWTX was testing its drug, EDG-7500, in patients with hypertrophic cardiomyopathy, a type of heart disease that thickens the heart muscle, making it harder to pump blood

** The drug showed no clinically meaningful changes in left ventricular ejection fraction (LVEF): a predictor of heart failure and no events of atrial fibrillation (afib) - irregular heart rate

** "Safety continued to look clean with no clinically meaningful LVEF drops, and no LVEF excursions <50%" - RBC Capital Markets

** "Of note, EWTX reported an additional new-onset afib case... We think this still leaves questions on safety that'll take more than additional open-label data to disprove"- Stifel

** Including session moves, shares down 3.5% YTD

(Reporting by Sneha S K)

((Sneha.SK@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593403351"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593403351\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593403351?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 23:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593403351","market":"us","top_or_hot":-1,"title":"BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on positive safety data from heart disease drug trial</title></head><body><p>** Shares of biotech company Edgewise Therapeutics <span>EWTX.O</span> rise 20.4% to $26.18</p><p>** Company says its experimental heart disease drug showed positive safety results in a mid-stage study</p><p>** EWTX was testing its drug, EDG-7500, in patients with hypertrophic cardiomyopathy, a type of heart disease that thickens the heart muscle, making it harder to pump blood</p><p>** The drug showed no clinically meaningful changes in left ventricular ejection fraction (LVEF): a predictor of heart failure and no events of atrial fibrillation (afib) - irregular heart rate</p><p>** \"Safety continued to look clean with no clinically meaningful LVEF drops, and no LVEF excursions &lt;50%\" - RBC Capital Markets</p><p>** \"Of note, EWTX reported an additional new-onset afib case... We think this still leaves questions on safety that'll take more than additional open-label data to disprove\"- <a href=\"https://laohu8.com/S/SFB\">Stifel</a></p><p>** Including session moves, shares down 3.5% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-24 23:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> rises on positive safety data from heart disease drug trial</title></head><body><p>** Shares of biotech company Edgewise Therapeutics <span>EWTX.O</span> rise 20.4% to $26.18</p><p>** Company says its experimental heart disease drug showed positive safety results in a mid-stage study</p><p>** EWTX was testing its drug, EDG-7500, in patients with hypertrophic cardiomyopathy, a type of heart disease that thickens the heart muscle, making it harder to pump blood</p><p>** The drug showed no clinically meaningful changes in left ventricular ejection fraction (LVEF): a predictor of heart failure and no events of atrial fibrillation (afib) - irregular heart rate</p><p>** \"Safety continued to look clean with no clinically meaningful LVEF drops, and no LVEF excursions &lt;50%\" - RBC Capital Markets</p><p>** \"Of note, EWTX reported an additional new-onset afib case... We think this still leaves questions on safety that'll take more than additional open-label data to disprove\"- <a href=\"https://laohu8.com/S/SFB\">Stifel</a></p><p>** Including session moves, shares down 3.5% YTD </p><p> (Reporting by Sneha S K)</p><p> ((Sneha.SK@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251224:nL4N3XU0PX:1","article_id":"2593403351","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593403351","pubTimestamp":1766590027,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial** Shares of biotech company Edgewise Therapeutics EWTX.O rise 20.4% to $26.18** Company says its experimental heart disease drug showed positive safety results in a mid-stage study** EWTX was testing its drug, EDG-7500, in patients with hypertrophic cardiomyopathy, a type of heart disease that thickens the heart muscle, making it harder to pump blood** The drug showed no clinically meaningful changes in left ventricular ejection fraction : a predictor of heart failure and no events of atrial fibrillation  - irregular heart rate** \"Safety continued to look clean with no clinically meaningful LVEF drops, and no LVEF excursions <50%\" - RBC Capital Markets** \"Of note, EWTX reported an additional new-onset afib case... We think this still leaves questions on safety that'll take more than additional open-label data to disprove\"- Stifel** Including session moves, shares down 3.5% YTD   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"BUZZ-Edgewise Therapeutics因心脏病药物试验的积极安全性数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":0.9},"content_text":"BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial** Shares of biotech company Edgewise Therapeutics EWTX.O rise 20.4% to $26.18** Company says its experimental heart disease drug showed positive safety results in a mid-stage study** EWTX was testing its drug, EDG-7500, in patients with hypertrophic cardiomyopathy, a type of heart disease that thickens the heart muscle, making it harder to pump blood** The drug showed no clinically meaningful changes in left ventricular ejection fraction (LVEF): a predictor of heart failure and no events of atrial fibrillation (afib) - irregular heart rate** \"Safety continued to look clean with no clinically meaningful LVEF drops, and no LVEF excursions <50%\" - RBC Capital Markets** \"Of note, EWTX reported an additional new-onset afib case... We think this still leaves questions on safety that'll take more than additional open-label data to disprove\"- Stifel** Including session moves, shares down 3.5% YTD  (Reporting by Sneha S K) ((Sneha.SK@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}